Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anat Loewenstein

Showing results (21-30 of 375) with videos related to

Pageof 38
Sort By:
Pharmaceutics|August 28, 2021
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the LiteratureIrini Chatziralli, Anat Loewenstein
Developments in Ophthalmology|March 29, 2017
Drug Delivery to the Posterior Segment of the EyeElad Moisseiev, Anat Loewenstein
Eye (London, England)|September 1, 2019
How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical questionElad Moisseiev, Anat Loewenstein
Eye (London, England)|September 21, 2019
Abicipar pegol-a novel anti-VEGF therapy with a long duration of actionElad Moisseiev, Anat Loewenstein
JAMA Ophthalmology|December 16, 2021
Development in Smartphone Technologies and the Advancement of Home Vision MonitoringDinah Zur, Anat Loewenstein
Current Pharmaceutical Design|January 25, 2019
Novel Long-acting Pharmacotherapy for Exudative Age Related Macular DegenerationElad Moisseiev, Anat Loewenstein
Retina (Philadelphia, Pa.)|December 19, 2024
ReplyElad Moisseiev, Anat Loewenstein
Eye (London, England)|October 14, 2021
Should we still be performing macular laser for non-centre involving diabetic macular oedema? YesDinah Zur, Anat Loewenstein
Clinical & Experimental Ophthalmology|October 3, 2021
Is there a light at the end of the gender inequality tunnel?Dinah Zur, Anat Loewenstein
Eye (London, England)|November 28, 2019
Initial treatment of macular oedema due to central retinal vein occlusion-which anti-VEGF agent to choose?Elad Moisseiev, Anat Loewenstein
Pageof 38

Showing results (21-30 of 375) with videos related to

Sort By:
Pageof 38
Pharmaceutics|August 28, 2021
Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the LiteratureIrini Chatziralli, Anat Loewenstein
Developments in Ophthalmology|March 29, 2017
Drug Delivery to the Posterior Segment of the EyeElad Moisseiev, Anat Loewenstein
Eye (London, England)|September 1, 2019
How to manage patients with center-involving diabetic macular edema and good visual acuity? An answer to a common clinical questionElad Moisseiev, Anat Loewenstein
Eye (London, England)|September 21, 2019
Abicipar pegol-a novel anti-VEGF therapy with a long duration of actionElad Moisseiev, Anat Loewenstein
JAMA Ophthalmology|December 16, 2021
Development in Smartphone Technologies and the Advancement of Home Vision MonitoringDinah Zur, Anat Loewenstein
Current Pharmaceutical Design|January 25, 2019
Novel Long-acting Pharmacotherapy for Exudative Age Related Macular DegenerationElad Moisseiev, Anat Loewenstein
Retina (Philadelphia, Pa.)|December 19, 2024
ReplyElad Moisseiev, Anat Loewenstein
Eye (London, England)|October 14, 2021
Should we still be performing macular laser for non-centre involving diabetic macular oedema? YesDinah Zur, Anat Loewenstein
Clinical & Experimental Ophthalmology|October 3, 2021
Is there a light at the end of the gender inequality tunnel?Dinah Zur, Anat Loewenstein
Eye (London, England)|November 28, 2019
Initial treatment of macular oedema due to central retinal vein occlusion-which anti-VEGF agent to choose?Elad Moisseiev, Anat Loewenstein
Pageof 38